MDB Capital Holdings LLC
02/26/2026 | Press release | Archived content
The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron
The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron
Published Date: 02.26.2026
Wegovy and Zepbound (semaglutide, tirzepatide) built a $71 billion market by treating less than 5% of eligible patients. The other 95% remain untreated, not because the drugs don't work, but because needles, cold chains, and $1,000-per-month pricing don't scale. Fifty oral small-molecule programs are now racing to close that gap. Efficacy is converging. Deal flow is public. The question that will determine which become twenty-year franchises and which become commodities is the one most investors can't answer: how deep is the IP protecting each molecule? PatentVest reviewed over 1,200 patent documents across 26 programs to find out.
MDB Capital is a wholly-owned subsidiary of MDB Capital Holdings (Nasdaq: MDBH) and a broker-dealer registered with the U.S. Securities and Exchange Commission, a member of FINRA and a member of SIPC. Securities trading, account management, and investment banking services are offered by MDB Capital.
PatentVest, Inc. is a wholly owned subsidiary of MDB Capital Holdings and an affiliated company of MDB Capital.
All patent portfolio data and analysis in this report are based on publicly available information as of February 2026, sourced through PatentVest, our proprietary global patent database. While every effort has been made to ensure accuracy and completeness, the findings may not reflect unpublished, pending, or confidential filings. Companies may hold additional IP assets that are not yet publicly disclosed. This report should be considered a snapshot, not a definitive account, of current IP positions.
Information in this message from employees of MDB Capital or an affiliated company is based upon information that is believed to be reliable. However, neither MDB Capital nor its affiliates warrant its completeness, accuracy or adequacy.
MDB Capital Holdings LLC published this content on February 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 20, 2026 at 21:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]